依达拉奉治疗动脉瘤性蛛网膜下腔出血的临床观察
依达拉奉；脑动脉瘤；出血,蛛网膜下腔,,依达拉奉；脑动脉瘤；出血，蛛网膜下腔,1资料与方法,2结果,3讨论,参考文献
【摘 要】 目的 评价依达拉奉对动脉瘤性蛛网膜下腔出血(SAH)后继发性脑损伤的近期及远期治疗效果。方法 动脉瘤性SAH患者64例随机分为治疗组和对照组，每组32例。所有患者均予常规治疗，并行动脉瘤夹闭术，治疗组在上述治疗基础上加用依达拉奉注射液30 mg静脉滴注，每日2次共14 d。2组分别于治疗前及治疗后7 d、14 d、28 d、90 d进行神经功能缺损评分及疗效评定。结果 治疗组在治疗后7 d、14 d、28 d及90 d治疗总有效率均明显高于对照组(P<0.01)。治疗组近期疗效(1～14 d)明显优于对照组(P<0.05)，而远期疗效(15～90 d)差异无显著意义(P>0.05)。结论 依达拉奉作为一种新型羟自由基清除剂，用于动脉瘤性SAH治疗安全、有效。【关键词】 依达拉奉；脑动脉瘤；出血，蛛网膜下腔
Clinical evacuation of edaravone in treatment of aneurismal subarachnoid hemorrhage MA Piyong,GAO Yufei,ZHAO Yong.Department of Emergency and Neurosurgery,ChinaJapan Union Hospital of Jilin University,Changchun 130033,China
【Abstract】 Objective To evaluate the efficacy of edaravone in treatment of aneurismal subarachnoid hemorrhage.Methods 64 patients with intracranial aneurysm were randomly divided into treatment group (n=32) and control group (n=32).All the patients,undergone aneurysm clipping,were given the same treatment except for the dose of edavane,30mg once,twice a day for 14 days in treatment group.The neurological function deficit scores and the evaluation of therapeutic effects were observed in both groups after treatment with edaravone at 7 days,14 days,28 days and 3 months.Results As compared with control group,treatment group had higher effective rate after treatment with edaravone at 7 days,14 days,28 days and 3 months.Conclusion Edaravone as a new hydroxyfree radical scavenger,could be used to treat aneurismal subarachnoid hemorrhage.The treatment is safe and effective. ......
您现在查看是摘要页，全文长 8663 字符。